Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc. (MRKR)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -3,179,278 | -1,703,210 | -1,998,662 | -8,461,748 |
| Stock-based compensation | 178,422 | 111,131 | 33,279 | 393,130 |
| Deferred revenue | NaN | -378,176 | 0 | 1,352,975 |
| Prepaid expenses and other current assets | -240,697 | -467,974 | -151,865 | 794,872 |
| Other receivables | 7,900 | -295,753 | -9,182 | -672,368 |
| Related party payable | 1,001,229 | -328,315 | -328,316 | -1,053,869 |
| Accounts payable and accrued expenses | 614,301 | -365,263 | -603,224 | 513,917 |
| Deferred grant income | -251,663 | NaN | NaN | NaN |
| Net cash used in operating activities | -1,404,192 | -1,900,106 | -2,735,876 | -7,378,099 |
| Proceeds from issuance of common stock, net | NaN | 0 | 9,863,883 | NaN |
| Proceeds from exercise of warrants and stock options | NaN | 0 | 0 | 605 |
| Net cash provided by financing activities | NaN | 0 | 9,863,883 | 605 |
| Net decrease in cash, cash equivalents, and restricted cash | -1,404,192 | -1,900,106 | 7,128,007 | -7,377,494 |
| Cash, cash equivalents, and restricted cash at beginning of the period | 17,042,847 | 18,942,953 | 19,192,440 | NaN |
| Cash, cash equivalents, and restricted cash at end of the period | 15,638,655 | 17,042,847 | 18,942,953 | NaN |